Showing 3251-3260 of 5646 results for "".
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu
- OCT Angiography Demonstrates Retinal Involvement in Amblyopiahttps://modernod.com/news/oct-angiography-demonstrates-retinal-involvement-in-amblyopia/2478003/Optical coherence tomography angiography (OCT-A) could play a role in diagnosing and understanding the pathogenesis of amblyopia, researchers in Hong Kong report, according to a Reuters report. “Our study, utilizing high-reso
- Biogen Boosts Gene Therapy Strategy With Harvard Pact Focused on Inherited Eye Diseasehttps://modernod.com/news/biogen-boosts-gene-therapy-strategy-with-harvard-pact-focused-on-inherited-eye-disease/2477996/Mutations in more than 270 genes have been implicated in inherited eye diseases like retinitis pigmentosa. Now, Biogen has formed a research pact with Harvard’s Massachusetts Eye and Ear that’s aimed at developing a gene therapy to help some patients with these blinding diseases, according to a F
- Accelmed Partners Completes Acquisition of TearLabhttps://modernod.com/news/accelmed-partners-completes-acquisition-of-tearlab/2477991/Private equity firm Accelmed Partners II (AP-II) completed its $25 million acquisition of dry eye device maker TearLab. As a newly formed private company, TearLab is now positioned to pursue further development of its next-generation Discovery platform and seek out targeted acquisition opp
- Laboratory Studies Confirm Betadine Antiseptic Products’ Effectiveness Against COVID-19 Virushttps://modernod.com/news/laboratory-studies-confirm-betadine-antiseptic-products-effectiveness-against-covid-19-virus/2477989/Mundipharma announced that laboratory testing at the Duke-NUS Medical School in Singapore has confirmed the effectiveness of its Betadine antiseptic products against the novel coronavirus (SARS-CoV-2). Testing has demonstrated Betadine strong in-vitro virucidal activity, killing 99.99% of
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- FAH Demands More Time For Providers to Repay Advance Medicare Payments Due Soonhttps://modernod.com/news/fah-demands-more-time-for-providers-to-repay-advance-medicare-payments-due-soon/2477909/The Federation of American Hospitals is imploring Medicare to give providers more time to repay advanced Medicare loans sent out to help providers facing a financial crisis from COVID-19, according to a FierceHealthcare
- Iveric Bio Announces Positive Zimura 18 Month Data Supporting the 12 Month Efficacy Findings for GA Secondary to AMDhttps://modernod.com/news/iveric-bio-announces-positive-zimura-18-month-data-supporting-the-12-month-efficacy-findings/2479517/Iveric bio announced positive 18 month results from the company’s first phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The 18 month data support